Delivering Pharma’s only Comprehensive Data, Consulting, and Business Process Platform for Market Access

IntegriChain is on a mission… to help all stakeholders in the life sciences industry drive access.

We do this through our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts and pricing, gross-to-net, channel, and patient services – unlocking strategic payer, provider, pharmacy and patient access insights for our life sciences customers.

Proven Success at Making Life Sciences Data Actionable

We provide the strategy, data, applications, and business process infrastructure for market access and therapy commercialization. More than 400 manufacturers rely on our consulting expertise and ICyte Platform to orchestrate their commercial and government payer contracting, patient services, and distribution channels. ICyte is the first and only platform that unites the financial, operational, and commercial data sets required to support therapy access in the era of specialty and precision medicine. With ICyte, pharmaceutical innovators can digitalize their market access operations, freeing up resources to focus on more data-driven decision support.

IntegriChain has expanded our business to include managed services and an application platform across key related disciplines including government pricing, rebate management, and gross-to-net. Today we are the leading provider of contracts and pricing and gross-to-net managed services, advisory services, and system integration services.

IntegriChain now has the largest managed services platform in the industry, supporting more than 200 manufacturer customers every day. We also have grown our team of world-class commercialization and market access experts to more than 600.

Today, our global IntegriChain team is uniquely positioned to address critical therapy access challenges throughout the drug commercialization life cycle, ensuring that patients have access to their life-saving and life-changing medicines as needed and minimizing the chances that they forego therapy.

From Launch to Full Product Lifecycle Support

We recently acquired Blue Fin Group, Pharma’s leading commercialization consulting firm. Together, manufacturers turn to us for access, commercialization, GTN, and channel strategy and insights. Blue Fin Group aligns all the elements of marketing, market access, field sales, pharmacy and distribution, and patient services as a seamless commercial strategy that helps optimize patient outcomes. Together, our combined team of experts focuses on solving your biggest access challenges: patient funnel pull through and GTN optimization–all powered by ICyte’s data and insights for commercial, GTN, and “what if” analyses for complete optimization. Simply put, Blue Fin Group helps develop commercialization strategies, and IntegriChain operationalizes them.

Trusted by World-Class Life Sciences Innovators of all Size

From improving launch readiness to enabling regulatory compliance and access to government programs as well as optimizing distribution and patient access strategies and programs, IntegriChain plays a vital role in enabling our customers to make better and faster payer, channel, and patient support decisions. In fact, more than 400 life science manufacturers— ranging from pre-commercial manufacturers to Big Pharma and including all top-30 companies rely on IntegriChain’s world-class data, managed, and professional services. Together, we support more than 60% of product launches, including half of all first-time launches. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm.

We are passionate about our customers’ mission – improving the lives of patients – and view it as our own.